Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Nicola Klein and Ousseny Zerbo.
Nicola Klein
Connection Strength
20.003
Ousseny Zerbo
  1. Risk of Immune Thrombocytopenic Purpura Recurrence Following Second Measles-Containing Vaccine Dose. Pediatrics. 2025 Aug 01; 156(2).
    View in: PubMed
    Score: 0.928
  2. Influenza Vaccination During Pregnancy and Infant Influenza in the First 6 Months of Life. Obstet Gynecol. 2025 Jun 26; 146(2):e36-e42.
    View in: PubMed
    Score: 0.922
  3. Recombinant Zoster Vaccination and Risk of Postherpetic Neuralgia or Zoster Ophthalmicus. JAMA Netw Open. 2025 Jun 02; 8(6):e2514615.
    View in: PubMed
    Score: 0.918
  4. Incidence and Risk of Coronavirus Disease 2019 Hospitalization Among Unvaccinated Children. Influenza Other Respir Viruses. 2024 Oct; 18(10):e70022.
    View in: PubMed
    Score: 0.876
  5. Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting. Ann Intern Med. 2024 Jan 09.
    View in: PubMed
    Score: 0.833
  6. Effectiveness of COVID-19 vaccination during pregnancy by circulating viral variant. AJOG Glob Rep. 2023 Nov; 3(4):100264.
    View in: PubMed
    Score: 0.812
  7. Individual and neighborhood factors associated with being unvaccinated against COVID-19 among pregnant persons. Hum Vaccin Immunother. 2023 08 01; 19(2):2256042.
    View in: PubMed
    Score: 0.808
  8. Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life. Nat Commun. 2023 Feb 28; 14(1):894.
    View in: PubMed
    Score: 0.785
  9. Maternal SARS-CoV-2 Vaccination and Infant Protection Against SARS-CoV-2 During the First 6 Months of Life. Res Sq. 2022 Oct 18.
    View in: PubMed
    Score: 0.765
  10. Safety of Live-Attenuated Vaccines in Children Exposed to Biologic Response Modifiers in Utero. Pediatrics. 2022 07 01; 150(1).
    View in: PubMed
    Score: 0.750
  11. Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders. Vaccine. 2022 Apr 20; 40(18):2568-2573.
    View in: PubMed
    Score: 0.735
  12. Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness. Expert Rev Vaccines. 2021 Oct 08; 1-9.
    View in: PubMed
    Score: 0.713
  13. Population-based assessment of risks for severe COVID-19 disease outcomes. Influenza Other Respir Viruses. 2021 Aug 25.
    View in: PubMed
    Score: 0.707
  14. Individual and Neighborhood Factors Associated With Failure to Vaccinate Against Influenza During Pregnancy. Am J Epidemiol. 2020 11 02; 189(11):1379-1388.
    View in: PubMed
    Score: 0.668
  15. Identification and description of mumps cases in a non-outbreak setting and evaluation of the effectiveness of mumps-containing vaccines over time. Hum Vaccin Immunother. 2020 12 01; 16(12):3098-3102.
    View in: PubMed
    Score: 0.647
  16. Parental risk factors for fever in their children 7-10 days after the first dose of measles-containing vaccines. Hum Vaccin Immunother. 2020 04 02; 16(4):875-880.
    View in: PubMed
    Score: 0.624
  17. Acellular Pertussis Vaccine Effectiveness Over Time. Pediatrics. 2019 07; 144(1).
    View in: PubMed
    Score: 0.606
  18. Factors Affecting Vaccination in Children and Their Siblings After Autism Spectrum Disorder Diagnosis-Reply. JAMA Pediatr. 2018 Oct 01; 172(10):985-986.
    View in: PubMed
    Score: 0.578
  19. Vaccination Patterns in Children After Autism Spectrum Disorder Diagnosis and in Their Younger Siblings. JAMA Pediatr. 2018 May 01; 172(5):469-475.
    View in: PubMed
    Score: 0.562
  20. Use of acellular pertussis vaccines in the United States: can we do better? Expert Rev Vaccines. 2017 12; 16(12):1175-1179.
    View in: PubMed
    Score: 0.541
  21. Concordance Between Maternal and Infant COVID-19 and Influenza Vaccination Status. Pediatrics. 2026 Jul 01; 158(1).
    View in: PubMed
    Score: 0.247
  22. Geographic Variation in Measles Vaccine Coverage Among Children Aged 7 Years in Northern California. JAMA Netw Open. 2026 Jul 01; 9(7):e2626224.
    View in: PubMed
    Score: 0.247
  23. SARS-CoV-2 Vaccination Before and During Pregnancy and Prevention of Infant COVID-19 Infection. Pediatrics. 2026 May 01; 157(5).
    View in: PubMed
    Score: 0.244
  24. Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults: A Cluster Randomized Crossover Study. JAMA Netw Open. 2026 May 01; 9(5):e2610120.
    View in: PubMed
    Score: 0.244
  25. Effectiveness of 2023-2024 Coronavirus Disease 2019 (COVID-19) Vaccines in Pregnant Women. Obstet Gynecol. 2026 Apr 01; 147(4):569-573.
    View in: PubMed
    Score: 0.238
  26. Effectiveness of 5-pertussis-component tetanus, diphtheria, and acellular pertussis (Tdap5) vaccination in pregnancy at preventing infant pertussis. Am J Obstet Gynecol. 2026 Apr; 234(4):1172-1182.
    View in: PubMed
    Score: 0.237
  27. Effectiveness of Nirsevimab Against RSV and RSV-Related Events in Infants. Pediatrics. 2025 Aug 01; 156(2).
    View in: PubMed
    Score: 0.232
  28. Vaccination During Pregnancy in the Vaccine Safety Datalink, 2002-2022. Pediatr Infect Dis J. 2025 Feb 01; 44(2S):S105-S107.
    View in: PubMed
    Score: 0.224
  29. Informing Maternal Immunization Trials: An Observational Study to Assess Background Rates of Maternal, Pregnancy, and Neonatal/Infant Outcomes. Pediatr Infect Dis J. 2025 Feb 01; 44(2S):S130-S134.
    View in: PubMed
    Score: 0.224
  30. Uptake of Maternal RSV Vaccination and Infant Nirsevimab Among Infants Born October 2023 to March 2024. JAMA Netw Open. 2025 Jan 02; 8(1):e2453696.
    View in: PubMed
    Score: 0.223
  31. Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents. Pediatrics. 2023 05 01; 151(5).
    View in: PubMed
    Score: 0.199
  32. Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. J Infect Dis. 2023 Jan 23.
    View in: PubMed
    Score: 0.195
  33. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Vaccine. 2022 08 19; 40(35):5153-5159.
    View in: PubMed
    Score: 0.188
  34. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
    View in: PubMed
    Score: 0.183
  35. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med. 2021 Sep 08.
    View in: PubMed
    Score: 0.177
  36. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021 Sep 03.
    View in: PubMed
    Score: 0.177
  37. Genetic associations with a fever after measles-containing vaccines. Hum Vaccin Immunother. 2021 06 03; 17(6):1763-1769.
    View in: PubMed
    Score: 0.169
  38. Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season. PLoS One. 2020; 15(2):e0229279.
    View in: PubMed
    Score: 0.159
  39. Influenza Vaccination in the First Trimester of Pregnancy and Risk of Autism Spectrum Disorder-Reply. JAMA Pediatr. 2017 06 01; 171(6):601-602.
    View in: PubMed
    Score: 0.132
  40. No association between influenza vaccination during pregnancy and adverse birth outcomes. Vaccine. 2017 05 31; 35(24):3186-3190.
    View in: PubMed
    Score: 0.131
  41. Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder. JAMA Pediatr. 2017 Jan 02; 171(1):e163609.
    View in: PubMed
    Score: 0.128
  42. Kaiser Permanente Northern California pregnancy database: Description and proof of concept study. Vaccine. 2016 11 04; 34(46):5519-5523.
    View in: PubMed
    Score: 0.126
  43. Effectiveness of 2023-2024 COVID-19 Vaccines in Children in the United States. Pediatrics. 2025 Dec 01; 156(6).
    View in: PubMed
    Score: 0.059
  44. Influenza Vaccination Among Pregnant People Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. Obstet Gynecol. 2023 09 01; 142(3):636-639.
    View in: PubMed
    Score: 0.051
  45. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 17; 71(53):1637-1646.
    View in: PubMed
    Score: 0.049
  46. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023 03 01; 6(3):e232598.
    View in: PubMed
    Score: 0.049
  47. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 30; 71(5152):1616-1624.
    View in: PubMed
    Score: 0.048
  48. Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022. J Infect Dis. 2022 Nov 23.
    View in: PubMed
    Score: 0.048
  49. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022. MMWR Morb Mortal Wkly Rep. 2022 Oct 21; 71(42):1335-1342.
    View in: PubMed
    Score: 0.048
  50. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022 10 03; 379:e072141.
    View in: PubMed
    Score: 0.048
  51. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. JAMA Netw Open. 2022 09 01; 5(9):e2233273.
    View in: PubMed
    Score: 0.047
  52. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. MMWR Morb Mortal Wkly Rep. 2022 Jul 22; 71(29):931-939.
    View in: PubMed
    Score: 0.047
  53. Safety of COVID-19 Vaccination in US Children Ages 5-11 Years. Pediatrics. 2022 May 18.
    View in: PubMed
    Score: 0.046
  54. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 01; 71(13):495-502.
    View in: PubMed
    Score: 0.046
  55. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
    View in: PubMed
    Score: 0.046
  56. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Jan 21; 71(4):139-145.
    View in: PubMed
    Score: 0.045
  57. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021. Am J Transplant. 2022 01; 22(1):306-314.
    View in: PubMed
    Score: 0.045
  58. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
    View in: PubMed
    Score: 0.045
  59. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.045
  60. COVID-19 Vaccination Coverage Among Insured Persons Aged =16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 16; 70(28):985-990.
    View in: PubMed
    Score: 0.044
  61. Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. Ther Adv Drug Saf. 2021; 12:20420986211021233.
    View in: PubMed
    Score: 0.044

© 2026 Kaiser Permanente

Your Privacy Choices